摘要
近年来,有关程序性死亡受体1 (programmed death-1,PD-1)及其配体(programmed death-1 ligand,PD-L1)抑制剂的研究取得突破性进展,迅速改变着非小细胞肺癌(non-small cell lung cancer,NSCLC)的治疗模式。但表皮生长因子受体(epidermalgrowthfactorreceptor,EGFR)突变患者应用PD-1/PD-L1抑制剂的治疗效果并不理想。既往研究显示,肿瘤细胞PD-L1表达率与免疫抑制剂治疗效果存在相关性。但目前EGFR突变对PD-L1表达的影响并不能达成一致。我们将对相关研究进行总结,以期对基础研究或临床治疗有所帮助。
Researches on the inhibitors of programmed death-1(PD-1) and programmed death-1 ligand(PD-L1)enjoy considerable breakthroughs in recent years,which has brought relative changes in the therapeutic model of non-small cell lung cancer(NSCLC) at an unexpected speed.However,it seems that PD-1/PD-L1 inhibitors are less effective in patients with epidermal growth factor receptor(EGFR) mutation than those without.Previous studies have shown that the expression rate of PD-L1 on tumor cells is correlated with the therapeutic effect of PD-1/PD-L1 inhibitors.Yet,there is no complete agreement on the effect of EGFR mutation on PD-L1 expression.In this review,relevant studies will be summarized with an expectation of making some contributions to basic researches and to the clinical treatment.
作者
智晓玉
李卫威
王少伟
汪进良
Xiaoyu ZHI;Weiwei LI;Shaowei WANG;Jinliang WANG(Department of Medical Oncology,the First Medical Center of Chinese PLA General Hospital,Beijing 100853,China;Department of Medical Oncology,the Hospital of 81st Group Army PLA,Zhangjiakou 075000,China;Key Laboratory of Cancer Center,the First Medical Center of Chinese PLA General Hospital,Beijing 100853,China)
出处
《中国肺癌杂志》
CAS
CSCD
北大核心
2019年第12期779-785,共7页
Chinese Journal of Lung Cancer
基金
解放军总医院医疗大数据研发项目（No.2017MBD-013）资助~~
